000			01183 a2200301 4500
005			20250516013224.0
264		0	_c20110307
008			201103s 0 0 eng d
022			_a2162-5514
024	7		_a10.1016/B978-0-12-381326-8.00008-9 _2doi
040			_aNLM _beng _cNLM
100	1		_aMarin, Concepció
245	0	0	_aCatechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment. _h[electronic resource]
260			_bInternational review of neurobiology _c2010
300			_a191-205 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAnimals
650	0	4	_aAntiparkinson Agents _xtherapeutic use
650	0	4	_aCatechol O-Methyltransferase _xtherapeutic use
650	0	4	_aCatechol O-Methyltransferase Inhibitors
650	0	4	_aDisease Models, Animal
650	0	4	_aDrug Therapy, Combination
650	0	4	_aLevodopa _xtherapeutic use
650	0	4	_aParkinson Disease, Secondary _xdrug therapy
700	1		_aObeso, J A
773	0		_tInternational review of neurobiology _gvol. 95 _gp. 191-205
856	4	0	_uhttps://doi.org/10.1016/B978-0-12-381326-8.00008-9 _zAvailable from publisher's website
999			_c20391630 _d20391630